Wuhan General Group (OTCMKTS:WUHN) versus Xometry (NASDAQ:XMTR) Head-To-Head Contrast

Wuhan General Group (OTCMKTS:WUHN) and Xometry (NASDAQ:XMTR) are both industrials companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, profitability, valuation and risk.

Institutional and Insider Ownership

97.3% of Xometry shares are owned by institutional investors. 61.1% of Wuhan General Group shares are owned by insiders. Comparatively, 9.7% of Xometry shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Wuhan General Group and Xometry’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Wuhan General Group	N/A	N/A	N/A
Xometry	-8.99%	-5.49%	-2.24%

Risk and Volatility

Wuhan General Group has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Xometry has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Wuhan General Group and Xometry, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Wuhan General Group	0	0	0	0	0.00
Xometry	1	5	5	0	2.36

Xometry has a consensus target price of $62.00, indicating a potential upside of 28.18%. Given Xometry’s stronger consensus rating and higher probable upside, analysts plainly believe Xometry is more favorable than Wuhan General Group.

Earnings and Valuation

This table compares Wuhan General Group and Xometry”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Wuhan General Group	N/A	N/A	N/A	N/A	N/A
Xometry	$686.63 million	3.65	-$61.74 million	($1.22)	-39.65

Wuhan General Group has higher earnings, but lower revenue than Xometry.

Summary

Xometry beats Wuhan General Group on 6 of the 10 factors compared between the two stocks.

About Wuhan General Group

Wuhan General Group (China), Inc., through its subsidiaries, researches, develops, and commercializes a range of cannabidiol (CBD)-based products under the Dr. AnnaRx brand for pharmacies. It also focuses on exploring and developing other indications for psilocybin new therapies that will enable patients who suffer from mental illness. The company offers its products for medical applications, including cancer, mental disorders, chronic pain, and others. Wuhan General Group (China), Inc. is headquartered in Pointe-Claire, Canada.

About Xometry

Xometry, Inc. operates an online marketplace that enables buyers to source custom-manufactured parts and assemblies in the United States and internationally. It provides computer numerical control manufacturing, sheet metal forming, and sheet cutting; 3D printing, including fused deposition modeling, direct metal laser sintering, PolyJet, stereolithography, selective laser sintering, binder jetting, carbon digital light synthesis, multi jet fusion, and lubricant sublayer photo-curing; and die casting, stamping, injection molding, urethane casting, tube cutting, and tube bending, as well as finishing services, rapid prototyping, and high-volume production services. It serves aerospace, healthcare, robotics, industrial, defense, energy, automotive, government, education, and consumer goods industries. The company was formerly known as NextLine Manufacturing Corp. and changed its name to Xometry, Inc. in June 2015. Xometry, Inc. was incorporated in 2013 and is headquartered in North Bethesda, Maryland.